Please assess the completion status of the following clinical trial:

Trial Title: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Detectable serum HBsAg at the Screening visit and at least 6 months prior~* HBeAg negative at Screening visit~* serum HBV DNA level \>2,000 IU/mL at Screening visit~* Elevated serum ALT≥2 ×ULN and \<10×ULN at Screening visit (excluding ALT elevations due to non-HBV reasons such as drug, alcohol etc)~Exclusion Criteria:~* Patient has a history of clinical signs/symptoms of hepatic decompensation (Child-Pugh Grade B or C) or ascites, esophageal variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis.~* Patient has a history of hepatocellular carcinoma (HCC) or suspected symptoms of HCC, such as suspicious foci on imaging studies and/or serum alpha-fetoprotein (AFP)\>50ng/mL.~* Patient has received treatment of nucleoside or nucleotide drugs whether approved or investigational before.~* Patient has received IFN or other immunomodulatory treatment within 52 weeks before Screening.~* Patient has a medical condition that requires frequent use of systemic acyclovir or famciclovir.~* Patient has a medical condition that requires frequent use of systemic corticosteroids, however topical and inhaled corticosteroids are allowed.~* Patient has used hepatotoxic drugs within one month.~* Patient has overtaken alcohol (\>40g/day) or abused illicit drugs in recent one year.~* Use of other investigational drugs at the time of enrollment.~* History of hypersensitivity to any of the study drugs (telbivudine or adefovir).~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test.~* Patient is co-infected with HCV, HDV or HIV.~* Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis).~* History of malignancy of any organ system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HBeAg Negative Hepatitis (Type: EXPERIMENTAL): HBeAg Negative Hepatitis patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).